Ozurdex Implant In Non Infectious Posterior Uveitis
-
Upload
dr-jagannath-boramani -
Category
Healthcare
-
view
215 -
download
3
Transcript of Ozurdex Implant In Non Infectious Posterior Uveitis
Ozurdex Implant in Non Infectious Posterior Uveitis
PRESENTING AUTHOR : Dr. UMESH BHAMMARKAR CO –AUTHOR: Dr. DEEPTI MEHTA
Dr. DIVYA NATARAJAN
INSTITUTE: LIONS CLUB OF HYDERABAD SADHURAM EYE HOSPITAL HYDERABAD
• Introduction:
• Posterior Uveitis is a severe site threatening diseases leading to blinding complications
• Ozurdex 0.7 mg slow sustained release biodegradable intravitreal implant is effective in non infectious posterior uveitis.
• Material and Methods:• Retrospective study of 3 eyes with noninfectious
Uveitic macular edema treated with Ozurdex implant with at least 12 months follow-up time.
• Macular edema was diagnosed by clinical examination, Fluorescein angiography and cirrus optical coherence tomography.
• Patients’ data were collected and included details of uveitis, ocular inflammation, best corrected visual acuity (BCVA) and OCT at baseline and each visit during follow-up.
• Number of injections and potential complications were recorded.
• Results: • 3 eyes (2patients) were included with
posterior uveitis.• Mean follow-up time was 16 months.• All three eyes of two patients showed
decrease inflammatory activity, visual gain (6 weeks follow up) and decreased central retinal thickness (6 months follow up).
• No recurrence or adverse side effects noted within Six months duration.
Sex, Age
Diagnosis BCVA FFA OCT No. of Ozurd
ex
Follow-up
Final BCV
A
M, 30
Posterior Uveitis
6/36 Parafoveal Leak
CME 1 1, 3, 6, Months
6 /12
F, 42
B/L Idiopathic Posterior Uveitis
6/24 Parafoveal Leak
CME 1 1, 3, 6 months
6/9
F, 42
B/L Idiopathic Posterior Uveitis
6/18 Parafoveal Leak
CME 1 1, 3, 6 months
6/9
Graph 1 – BCVA
Graph 2 – Central Retinal Thickness
OCT Before Ozurdex OCT After Ozurdex
1, Left Eye
2, Right Eye
2, Left Eye
Conclusion:• Treatment of Non – Infectious posterior Uveitis
with single dose of Dexamethasone implant proved to be efficacious in treatment of Intra Ocular inflammation with its benefit sustained over a period of 6 months.
• Patients are still under follow-up and if recurrence occurs, will plan for second dose of Ozurdex.
• Further prospective studies are needed to determine efficacy, duration of effect and side effects.
TAKE HOME MESSAGEPosterior Uveitis is a severe site
threatening diseases leading to blinding complications
Ozurdex 0.7 mg slow sustained release biodegradable intravitreal implant is effective in non infectious posterior uveitis.
Both FFA and OCT scan are helpful in diagnosis and monitoring the response to treatment.